Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
CNTX 
Context Therapeutics Inc (CNTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/23/2026: CNTX (4-star) is a STRONG-BUY. BUY since 37 days. Simulated Profits (75.38%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $5.57
1 Year Target Price $5.57
| 2 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 205.81M USD | Price to earnings Ratio - | 1Y Target Price 5.57 |
Price to earnings Ratio - | 1Y Target Price 5.57 | ||
Volume (30-day avg) 5 | Beta 1.95 | 52 Weeks Range 0.49 - 2.85 | Updated Date 02/23/2026 |
52 Weeks Range 0.49 - 2.85 | Updated Date 02/23/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.24 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -22.81% | Return on Equity (TTM) -33.68% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 6327554 | Price to Sales(TTM) - |
Enterprise Value 6327554 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.6 | Shares Outstanding 91879177 | Shares Floating 42717386 |
Shares Outstanding 91879177 | Shares Floating 42717386 | ||
Percent Insiders 1.18 | Percent Institutions 76.71 |
Upturn AI SWOT
Context Therapeutics Inc
Company Overview
History and Background
Context Therapeutics Inc. was founded in 2007. The company's history is marked by its focus on developing treatments for hormone-driven cancers, particularly breast and ovarian cancers. A significant milestone was the acquisition of Cyclacel Pharmaceuticals, Inc. in 2013, which brought its pipeline and operations under the Context Therapeutics umbrella. The company has since been actively engaged in clinical development and strategic partnerships.
Core Business Areas
- Oncology Drug Development: Context Therapeutics Inc. is primarily engaged in the research and development of novel therapeutics targeting hormone-dependent cancers. Their focus is on identifying and advancing drug candidates that address unmet medical needs in these indications.
Leadership and Structure
Context Therapeutics Inc. is led by a management team with expertise in drug development, clinical trials, and the pharmaceutical industry. The organizational structure is typical of a biotechnology company focused on R&D, with departments dedicated to research, clinical operations, regulatory affairs, and business development.
Top Products and Market Share
Key Offerings
- Product Name 1: CTx-012 (under development). This is a potential treatment for hormone-driven cancers. Specific market share data or revenue is not yet applicable as the product is in development. Competitors in the hormone-driven cancer space include companies like Pfizer, Novartis, and AstraZeneca, with their respective branded therapies.
Market Dynamics
Industry Overview
The oncology drug market is a rapidly growing and highly competitive sector driven by increasing cancer incidence, advancements in scientific understanding, and the demand for more effective and targeted therapies. The hormone-driven cancer segment, in particular, remains a significant area of focus for pharmaceutical research.
Positioning
Context Therapeutics Inc. positions itself as a developer of innovative therapies for specific niches within the oncology market, particularly hormone-driven cancers. Their competitive advantage lies in their focused approach and potential for novel mechanisms of action.
Total Addressable Market (TAM)
The total addressable market for hormone-driven cancers is substantial, encompassing billions of dollars globally. Context Therapeutics Inc. is positioned to capture a portion of this market with successful development and commercialization of its lead candidates. The TAM is further segmented by specific cancer types (e.g., breast, prostate, ovarian) and stages of disease.
Upturn SWOT Analysis
Strengths
- Focused research and development on a specific disease area (hormone-driven cancers).
- Potential for novel therapeutic mechanisms.
- Experienced management team in drug development.
Weaknesses
- Pipeline is still in early to mid-stage development, with no approved products.
- Reliance on external funding for continued research and development.
- Limited brand recognition and market presence compared to established pharmaceutical giants.
Opportunities
- Growing demand for targeted therapies in oncology.
- Potential for strategic partnerships and licensing agreements.
- Advancements in understanding cancer biology offering new therapeutic targets.
Threats
- High attrition rates in drug development.
- Intense competition from established and emerging biotechnology companies.
- Stringent regulatory approval processes.
- Patent expirations of existing treatments leading to generic competition.
Competitors and Market Share
Key Competitors
- Pfizer Inc. (PFE)
- Novartis AG (NVS)
- AstraZeneca PLC (AZN)
- Roche Holding AG (RHHBY)
Competitive Landscape
Context Therapeutics Inc. faces intense competition from large pharmaceutical companies with established portfolios of oncology drugs and significant R&D budgets. Their advantage lies in the potential for disruptive innovation with novel mechanisms of action in specific, underserved niches.
Growth Trajectory and Initiatives
Historical Growth: Historically, Context Therapeutics Inc.'s growth has been characterized by milestones in its research and development pipeline, including the progression of its drug candidates through clinical trials and strategic acquisitions or collaborations. Financial growth has been dependent on its ability to secure funding.
Future Projections: Future projections are contingent on the successful clinical development and regulatory approval of its drug candidates, particularly CTx-012. Analyst estimates would likely focus on the potential market penetration and revenue generation upon commercialization.
Recent Initiatives: Recent initiatives likely involve advancing clinical trials for its lead candidates, exploring new therapeutic targets, and potentially seeking strategic partnerships or collaborations to accelerate development and commercialization.
Summary
Context Therapeutics Inc. is a development-stage biotechnology company focused on hormone-driven cancers. Its strengths lie in its specialized research and experienced team, but it faces significant weaknesses due to its unproven pipeline and reliance on funding. Opportunities exist in the growing oncology market, but threats from competition and development risks are substantial. The company needs to successfully navigate clinical trials and secure funding to achieve its growth potential.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company public filings (SEC)
- Industry analysis reports
- Financial news outlets
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute financial advice. Investment in biotechnology companies, especially development-stage ones, carries significant risk. Investors should conduct their own due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Context Therapeutics Inc
Exchange NASDAQ | Headquaters Philadelphia, PA, United States | ||
IPO Launch date 2021-10-20 | Co-Founder, President, CEO & Director Mr. Martin A. Lehr | ||
Sector Healthcare | Industry Biotechnology | Full time employees 12 | |
Full time employees 12 | |||
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.